SNY Jun 2023 60.000 put
| Previous close | 12.20 |
| Open | 9.70 |
| Bid | 7.40 |
| Ask | 11.10 |
| Strike | 60.00 |
| Expiry date | 2023-06-16 |
| Day's range | 9.40 - 9.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 295 |
- Bloomberg
Sanofi, Regeneron’s Drug Succeeds in High-Stakes Lung Trial
(Bloomberg) -- Sanofi’s prescription drug Dupixent helped patients with a chronic lung disorder breathe better and regain lung function, opening a new avenue of growth for the blockbuster medicine. Most Read from BloombergFinally, a Serious Offer to Take Putin Off Russia’s HandsUS Fears a War-Weary World May Embrace China’s Ukraine Peace BidShort Seller Hindenburg Says ‘Another Big One’ Coming SoonAckman Warns of Accelerated Deposit Outflows After Fed DecisionJack Dorsey’s Block Falls After Hind
- GlobeNewswire
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placeboFirst and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to placebo (77 mL in FEV1) First and only biologic to demonstrate significant improvements in quality of life
